Generic Name and Formulations:
Ganciclovir 4.5mg; per implant; for intravitreal implantation.
Bausch Health Companies Inc.
Indications for VITRASERT:
Treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.
Adults and Children:
<9yrs: not recommended. ≥9yrs: Implant designed to release drug over 5–8 months. May be removed and replaced following depletion of ganciclovir.
External infection. Severe thrombocytopenia.
Should be administered by surgeon who has observed or assisted in surgical implantation of Vitrasert prior to attempting procedure. Monitor for extraocular CMV disease. Ophthalmologic follow-up advised at appropriate intervals. Pregnancy (Cat.C). Nursing mothers: not recommended.
Visual acuity loss of 3 lines or more, vitreous hemorrhage, retinal detachments, cataract formation/lens opacities, macular abnormalities, intraocular pressure spikes, optic disk/nerve changes, hyphemas, uveitis.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Comorbid Narcolepsy and Schizophrenia in Adolescents
- Ketamine in Electroconvulsive Therapy Accelerates Antidepressive Effects
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Prenatal Insecticide Exposure in Mother May Be Linked to Risk for Autism in Children